These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 7801146)
1. Rationale for the use of granulocyte-macrophage colony-stimulating factor in oncology. Aglietta M; Piacibello W; Pasquino P; Sanavio F; Stacchini A; Volta C; Monteverde A; Fubini L; Morelli S; Severino A Semin Oncol; 1994 Dec; 21(6 Suppl 16):5-9. PubMed ID: 7801146 [No Abstract] [Full Text] [Related]
2. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). Lieschke GJ; Burgess AW N Engl J Med; 1992 Jul; 327(1):28-35. PubMed ID: 1375975 [No Abstract] [Full Text] [Related]
3. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: double-edged swords. Wilson RF; Henry TD J Am Coll Cardiol; 2005 Nov; 46(9):1649-50. PubMed ID: 16256863 [No Abstract] [Full Text] [Related]
4. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. Root RK; Dale DC J Infect Dis; 1999 Mar; 179 Suppl 2():S342-52. PubMed ID: 10081506 [TBL] [Abstract][Full Text] [Related]
5. Use of granulocyte-macrophage colony-stimulating factor in leukopenic renal transplant recipients. Page B; Morin MP; Mamzer MF; Thervet E; Legendre C Transplant Proc; 1994 Feb; 26(1):283. PubMed ID: 8108982 [No Abstract] [Full Text] [Related]
6. Colony-stimulating factor use in the context of refined risk and benefit assessments. Crawford J Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):9-10. PubMed ID: 16736982 [No Abstract] [Full Text] [Related]
7. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. Hübel K; Dale DC; Liles WC J Infect Dis; 2002 May; 185(10):1490-501. PubMed ID: 11992286 [TBL] [Abstract][Full Text] [Related]
8. Granulocyte-Macrophage Colony Stimulating Factor: Current Knowledge and Perspectives of a New Growth Factor. Proceedings of a symposium. Cologne, Germany, March 1993. Semin Oncol; 1994 Dec; 21(6 Suppl 16):1-63. PubMed ID: 7801143 [No Abstract] [Full Text] [Related]
9. The American Society of Clinical Oncology guideline program. Winn RF; Smith TF Pharm Pract Manag Q; 1996 Apr; 16(1):31-8. PubMed ID: 10157738 [No Abstract] [Full Text] [Related]
11. Mean myeloperoxidase index in lymphoma transplants receiving recombinant granulocyte-macrophage colony stimulating factor. Tsakona CP; Khwaja A; Goldstone AH Bone Marrow Transplant; 1993 Apr; 11(4):345-6. PubMed ID: 8387371 [No Abstract] [Full Text] [Related]
12. [The role of leukomax (granulocyte-macrophage colony stimulating factor) in oncology and hematology]. Gorbunova VA Vopr Onkol; 1995; 41(1):21-8. PubMed ID: 7667936 [No Abstract] [Full Text] [Related]
13. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Wong SF; Chan HO Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284 [TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial. Skowron G; Stein D; Drusano G; Melbourne K; Bilello J; Mikolich D; Rana K; Agosti JM; Mongillo A; Whitmore J; Gilbert MJ J Infect Dis; 1999 Oct; 180(4):1064-71. PubMed ID: 10479132 [TBL] [Abstract][Full Text] [Related]
15. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies. Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099 [TBL] [Abstract][Full Text] [Related]
16. Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor: a phase I-II study. Mangan K; Mullaney M; Klumpp T; Goldberg S; Macdonald J Stem Cells; 1993 Sep; 11(5):445-54. PubMed ID: 8241955 [TBL] [Abstract][Full Text] [Related]
17. Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on neutrophil formation and function. Khwaja A; Linch DC Curr Opin Hematol; 1994 May; 1(3):216-20. PubMed ID: 9371285 [TBL] [Abstract][Full Text] [Related]
18. Changes in cytokine production during therapy with granulocyte-macrophage colony-stimulating factor in patients with chronic hepatitis B. Martín J; Quiroga JA; Bosch O; Carreño V Hepatology; 1994 Nov; 20(5):1156-61. PubMed ID: 7927247 [TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of granulocyte-macrophage colony-stimulating factor. Engelhard M; Brittinger G Semin Oncol; 1994 Dec; 21(6 Suppl 16):1-4. PubMed ID: 7801142 [No Abstract] [Full Text] [Related]
20. Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Pei XH; Nakanishi Y; Takayama K; Bai F; Hara N Br J Cancer; 1999 Jan; 79(1):40-6. PubMed ID: 10408691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]